Picard Medical Files 8-K
Ticker: PMI · Form: 8-K · Filed: Dec 9, 2025 · CIK: 2030617
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Picard Medical filed an 8-K on 12/9/25, likely containing important company updates.
AI Summary
On December 9, 2025, Picard Medical, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Picard Medical, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific financial or operational details that would indicate high risk.
Key Players & Entities
- Picard Medical, Inc. (company) — Registrant
- December 9, 2025 (date) — Date of earliest event reported
- Tucson (location) — Principal executive office city
- Delaware (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Picard Medical, Inc.?
The filing is for Regulation FD Disclosure and Financial Statements and Exhibits, as indicated by the Item Information section.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 9, 2025.
What is the principal executive office address for Picard Medical, Inc.?
The principal executive office is located at 1992 E Silverlake, Tucson, AZ, 85713.
In which state is Picard Medical, Inc. incorporated?
Picard Medical, Inc. is incorporated in Delaware.
What is the telephone number for Picard Medical, Inc.?
The registrant's telephone number is (520) 545-1234.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-12-09 16:15:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PMI The NYSE American, LL
Filing Documents
- picardmedical_8k.htm (8-K) — 24KB
- picardmedical_99-1.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- 0001829126-25-009836.txt ( ) — 224KB
- pmi-20251209.xsd (EX-101.SCH) — 3KB
- pmi-20251209_lab.xml (EX-101.LAB) — 33KB
- pmi-20251209_pre.xml (EX-101.PRE) — 22KB
- picardmedical_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 9, 2025, Picard Medical, Inc. issued a press release announcing an update regarding the SynCardia Total Artificial Heart. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein. The information in this report and the exhibits attached hereto shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 99.1 Picard Medical, Inc. Press Release dated December 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Picard Medical, Inc. By: /s/ Patrick NJ Schnegelsberg Name: Patrick NJ Schnegelsberg Title: Chief Executive Officer Dated: December 9, 2025 2